Early fast‐acting treatment strategy against generalized myasthenia gravis
Kimiaki Utsugisawa(National Hospital Organization Hanamaki Hospital), Masashi Aoki(Tohoku University), Naoki Kawaguchi(Chiba Hospital), Masayuki Masuda(Tokyo Medical University), Naoya Minami(National Hospital Organization Hokkaido Medical Center), Shingo Konno(Toho University), Yuriko Nagane(National Hospital Organization Hanamaki Hospital), Tomihiro Imai(Sapporo Medical University Hospital), Hiroyuki Murai(Kyushu University), Yasushi Suzuki(Aichi Gakuin University), Hidekazu Suzuki(Kindai University), Tetsuya Akaishi(Tohoku University Hospital), Emiko Tsuda(Sapporo Medical University Hospital), Akiyuki Uzawa(Chiba University)
Cited by 75
Related Papers
Interferon Regulatory Factor 6 ( <i>IRF6</i> ) Gene Variants and the Risk of Isolated Cleft Lip or Palate
|New England Journal of Medicine|2004|583
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
|Neurology Neuroimmunology & Neuroinflammation|2017|432
Mutations in BMP4 Are Associated with Subepithelial, Microform, and Overt Cleft Lip
|The American Journal of Human Genetics|2009|215
CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
|Journal of Neurology Neurosurgery & Psychiatry|2018|199
MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study: Table 1
|Journal of Neurology Neurosurgery & Psychiatry|2015|141